14763-24-7Relevant articles and documents
Proton transfer reactions of N-aryl triazolium salts: Unusual ortho-substituent effects
Tucker, David E.,Quinn, Peter,Massey, Richard S.,Collett, Christopher J.,Jasiewicz, David J.,Bramley, Christopher R.,Smith, Andrew D.,O'Donoghue, AnnMarie C.
, p. 108 - 115 (2015)
Previous studies of the C(3)-hydrogen/deuterium exchange reactions of the triazolium ion conjugate acids of triazolyl N-heterocyclic carbenes revealed a change of mechanism under acidic conditions with N1-protonation to a dicationic salt. Interestingly, the data suggested an increase in pKaN1 in the presence of a N-pentafluorophenyl substituent relative to other N-aryl substituents with hydrogens or methyl substituents rather than fluorines at the ortho-positions. To probe the presence of an apparent donor effect of a N-pentafluorophenyl substituent, which differs from the more common electron withdrawing effect of this group, we have studied the analogous deuterium exchange reactions of four triazolium salts with heteroatoms or heteroatom substituents in the 2-position and/or 6-position of the N-aryl ring. These include triazolium salts with N-2,4,6-tribromophenyl 11, N-2,6-dichlorophenyl 12, N-2-pyridyl 13 and N-2-pyrimidinyl 14 substituents. The log kex - pD profiles for 11, 12 and 14 were found to show similar trends at lower pDs as for the previously studied N-pentafluorophenyl triazolium salt, hence supporting the presence an apparent donor effect on pKaN1. Surprisingly, the log kex - pD profile for N-pyridyl salt 13 uniquely showed acid catalysis at lower pDs. We propose herein that this data is best explained by invoking an intramolecular general base role for the N-(2-pyridyl) substituent in conjunction with N1-protonation on the triazolium ring. Finally, the second order rate constants for deuteroxide ion catalysed C(3)-H/D exchange (kDO, M-1 s-1), which could be obtained from data at pDs 1.5, were used to provide estimates of C(3)-carbon acid pKaC3 values for the four triazolium salts 11-14.
Anthranilic diamides derivatives as potential ryanodine receptor modulators: Synthesis, biological evaluation and structure activity relationship
Liu, Jing-Bo,Li, Feng-Yun,Dong, Jing-Yue,Li, Yu-Xin,Zhang, Xiu-Lan,Wang, Yuan-Hong,Xiong, Li-Xia,Li, Zheng-Ming
, p. 3541 - 3550 (2018/06/19)
A series of novel anthranilic diamides derivatives (7a–s) containing halogen, trifluoromethyl group and cyano group were designed, synthesized, and characterized by melting point, 1H NMR, 13C NMR and elemental analyses. The bioactivity revealed that most of them showed moderate to excellent activities against oriental armyworm (Mythimna separata) and diamondback moth (Plutella xylostella). Above all, the larvicidal activity of 7o against oriental armyworm was 100% and 40% at 0.25 and 0.1 mg L?1, comparable to that of the standard chlorantraniliprole (100%, 0.25 mg L?1 and 20%, 0.1 mg L?1). What is more, 7o against diamondback moth displayed 90% insecticidal activity at 0.01 mg L?1, superior to chlorantraniliprole (45%, 0.01 mg L?1). The experiments 7o on the American cockroach (Periplaneta Americana) heart beating rates (Dorsal vessel) and contractile force were compared with chlorantraniliprole. In addition, 7o could affect the calcium homeostasis in the central neurons of the third larvae of oriental armyworm, which revealed that the ryanodine receptor is the potential target of 7o. The density functional theory (DFT) calculation results revealed the amide bridge, the benzene ring of anthraniloyl moiety and pyrazole ring might play an important role in the insecticidal activity through hydrophobic interactions and π-π conjugations.
Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase
-
Page/Page column 19, (2008/06/13)
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.